Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab ... of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody ...

If approved, it will compete with immunotherapies based on Roche's Tecentriq (atezolizumab) and AstraZeneca's Imfinzi (durvalumab), which were cleared by the FDA in 2020 and 2022, respectively.

Liver Unit, Faculty of Medicine, Imperial College London, St Mary's Hospital, 10th Floor QEQM Building, South Wharf Road, London W2 1NY, UK. Worldwide, hepatitis B virus is the major risk factor ...

The widespread utilization of chest CT scans has increased the importance of the proper evaluation of incidentally found lung nodules. The primary goal in the evaluation of these nodules is to ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

CALYPSO is a phase II study investigating savolitinib (600 mg once daily) + durvalumab (1,500 mg every four weeks) in advanced papillary RCC patients. Treatment-naïve or previously treated patients ...